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Running title: Regulation and role of apelin in mouse intestine. Apelin is the endogenous ligand for G protein-coupled receptor APJ 1, 2 acting under several 3 molecular forms processed from a 77-amino acids 4 precursor 3 .The active forms of apelin are present in peripheral tissues including lungs, heart, 5 adipose and pancreas (for reviews see 4, 5 ). In the gastrointestinaltract, mRNA apelin-6 expressing cells were found in rat and mouse stomach, in mouse duodenum, and in human 7 and mouse colon 1, 6 . APJ immunostaining has also been described in the epithelium, goblet 8 cells and crypt cell of the small intestine, and in the smooth muscle layer of rat 9 gastrointestinal tract 7 . APJ is also located in the enteric blood vessels 7 . Thus, the apelin/APJ 10 system may have a potential role in the digestive tract. 11
Recent studies established that apelin is involved in glucose homeostasis 8 . We 12 demonstrated that iv injection of physiological doses of apelin decreased glycemia and 13 stimulated glucose uptake in skeletal muscles of lean and obese insulin-resistant mice 9 . 14 Moreover, apelin-stimulated glucose transport in muscle was dependent of AMPK activation. 15
Similar results were described in cultured C2C12 myotubes by Yue et al. 10 . These authorsalso 16 showed that apelin-deficient mice exhibitdecreased insulin sensitivity 10 . Taken together, such 17 studies support the assumption that apelin plays a physiological role in glucose metabolism 18 and maintenance of insulin sensitivity 8 . 19 We demonstrated that leptin and resistin-, two adipokines secreted in the 20 gastrointestinal lumen by gastric and intestinal endocrine cells, regulate the activity of the 21 sugar transporters in enterocytes by an AMPK-dependent mechanism [11] [12] [13] . The net effect of 22 this regulation ofhexose transporters was an increase of sugar uptake with significant 23 consequences on splanchnic metabolism. Interestingly, the adipokine apelin shares several 24 features with these peptides such as i) the ability of being produced in gastrointestinaltract, ii) 25 an implication in glucose metabolism and iii) the control of insulin sensitivity via AMPK 10, 26 6 11 .Recent studies brought evidence of a putative regulation of apelin by glucose in different 1 tissues. Indeed, increased amounts of apelin in response to different glucose levels 14, 15, 27 2 were demonstrated in human endothelial as well as in pancreatic -cell. 3 This study was designed to characterize the relationship between apelin and glucose in 4 intestine.We showthat D-glucose promotes specifically Pyr-1-apelin-13 secretion in 5 intestine.We further demonstratein vitro and in vivothe capacity of apelin to increase glucose 6 flux from lumen toward the bloodstream by interacting with the APJ receptor present in 7 enterocytes. This effect appears to involve an AMPK-dependant control of SGLT-1 and 8 GLUT2 expression in apical enterocytes membrane by apelin. Moreover, pharmacological 9 inhibition of endogenousapelin action bya selective APJ antagonist resulted in a decrease of 10 glycemia,supporting the existence of a glucose/apelin cyclethat regulates intestinal 11 carbohydrates absorption. 12 13 METHODS 1 2
AnimalsMale C57BL/6J mice (Centre Elevage Janvier, Le Genest-St-Isle, France) had free 3 access to water and standard food. They were treated in accordance with European 4
Community guidelines concerning care and use of laboratory animals. 5 6 NanoLC-MS/MS analysis.The gastric contents were filtrated with a 10kDa membrane and 7 injected on a NanoRS 3500 chromatographic system (Dionex, Amsterdam, The Netherlands) 8 coupled to an LTQ-Orbitrap XL mass spectrometer (Thermo Fisher Scientific, Bremen, 9 Germany) . Five µL of each sample were separated on a 75 μm ID x 15 cm C18 column 10 (Proxeon Biosystems, Odense, Denmark). Peptides were eluted using a 5 to 50% linear 11 gradient of solvent B in 105 min (solvent A was 0.2% formic acid and solvent B was 0.2% 12 formic acid in 80% ACN). Full MS scans were acquired in the Orbitrap on the 300-2000 m/z 13 range with the resolution set to a value of 60000. An inclusion list corresponding to several 14 charge states (2+, 3+, 4+) of [Pyr-1]-apelin-13 was used to select these ions for CID 15 fragmentation and the resulting fragment ions were analyzed in the linear ion trap (LTQ). 16
Dynamic exclusion was employed within 60 s to prevent repetitive selection of the same 17 peptide. 18
19
Fluorescence immunohistochemical studies and confocal microscopy 20
Immunohistochemical staining was performed as previously described 16 using anti-APJ 21 polyclonal antibody (Novus Biologicals, 1/100), anti-apelin polyclonal antiserum (Covalab, 22 1/200) and anti-GLUT2 antibody (Abcam 54460, 1/100). Nuclei were stained with TOPRO-23 III (Invitrogen, 1/1000). Fluorescence analysis was performed utilizing a LSM510 Confocal 24 Laser Scanning microscope. Samples were visualized with a 25X objective lens Apochromat, N.A. 1,4, Oil) and excited using three laser lines (488, 543 and 633 nm). For 26 APJ and GLUT2 detection, control was achieved using an IgG mouse serum at the same 1 concentration as the antibody. The specificity of apelin immunostaining was tested using 2 primary antisera pre-absorbed with excess amount of homologous antigen ([Pyr1]-Apelin-13, 3 10 -6 mol/L). Densitometric quantifications of fluorescence intensity were assessed by Image J 4 software. The results represent the apelin-integrated density -(total area x mean fluorescence 5 of background) of 3 different pictures per mouse and 4 mice per group. 6 7 Tissue preparation and short-circuit measurement Mice were 16 h fasted and euthanized. 8
The proximal jejunum was dissected out and adjacent samples mounted in Ussing chambers. 9
The tissues were bathed with Krebs Ringer solution (KRB) with 10 mmol/L glucose at 37°C 10 (pH 7.4) and were gassed with 95% O 2 /5% CO 2 . Electrogenic ion transport was monitored as 11 previously described 11 . KRB alone (vehicle) or containing apelin (10 -10 to 10 -6 mol/L) was 12 added in the mucosal bath 2 min before the 10 mmol/L-glucose challenge. Similar tests were 13 performed with 100 nmol/L apelin incubated overnight at 4°C with 1/100 rabbit polyclonal 14 antibody raised against apelin (Covalab, France). 15
16
Transmural hexoses transport The experiments were performed using jejunal sacs from 17 fasted mice. The proximal jejunum was dissected out and rinsed in cold saline solution. 18
Jejunal sacs (4 cm long) were prepared for D-[1-14 C] glucose (49.5 mCi/mmol) transport as 19 previously described 11 . The corresponding jejunal sacs were filled with 1 ml of KRB solution 20 without (control) or with 1 nmol/L apelin and containing 0.02 μCi/ml of the isotopic tracer D-21 [1-14 C] glucose (49.5 mCi/mmol) and glucose to obtain a final concentration of 30 mmol/L. 22
Similarly, we studied the paracellular transport with 30 mmol/L mannitol and the isotopic 23 tracer D-[1-14 C] mannitol (59 mCi/mmol) at 0.2 μCi/ml. 24 25 SGLT-1, GLUT2, AMPKand APJ western blot Fastedanimals were anesthetized and 1 laparotomized for in situ experiments. Three jejunal segments (5 cm long) were tied and filled 2 with 3 ml of KRB without (control) or with 1 nmol/L apelin. After 3 min of in situ incubation, 3 3 ml of 60 mmol/L glucose solution were injected in the lumen to obtain a final concentration 4 of 30 mmol/L. After a further 5 min, these sacs were removed and opened along the 5 mesenteric border and the mucosa was scraped off on ice with a glass blade. 6
For APJ determination, mice were gavaged with water (control) or Pyr-1-apelin-13(200 7 pmol/kg in 100 µl). After 10 minutes, mice were euthanatized and whole intestine was 8 dissected on ice. The total cell protein extracts and the brush-border membranes (BBM) were 9 prepared from the scrapings as previously described 17 .Solubilized proteins were resolved by 10 electrophoresis on 10% SDS-PAGE gels and proceeded for immunoblotting. The 11 followingantibodies were used at a 1:1000 dilution: SGLT-1 (AB 1352; Chemicon 12 International); GLUT2, phospho-AMPK-α1/2 (Thr172) and AMPKα 1/2 (sc-9117, sc-33524, 13 sc-25792, respectively; Santa Cruz Biotechnology) and 1:500 for APJ (NLS 64, Novus 14 Biologicals) . The intensity of the specific immunoreactive bands was quantified using NIH 15 Image (Scion). 16
17
In vivo luminal apelin secretion Fasted C57BL/6J mice were orally loaded by 100 l of D-18 glucose solution (0.5 or 1 g/ml) or water (control). After 10 minutes, mice were 19 euthanatized, whole intestine was dissected and the luminal content gently collected and 20 immediately frozen. 21
22
Apelin secretion and immunoblotting from everted intestinal sacsWhole proximal 23 intestine was harvested, rinsed, everted and filled with PBS. Then, 1 cm long everted-24 intestine sacs were incubated in gassed and warmed PBS with or without glucose (5 and 30 1 mmol/L). Fifty l of media were collected at time 5, 30 and 60 min of incubation and 2 immediately frozen in liquid nitrogen before a column-filtration step (Amicon Ultra, 10,000 3 MWCO, Millipore) and measure of apelin concentration. To normalize results obtained, 4 each sac was collected for protein quantification. The same experiments were done to 5 determinate apelin-77 content in jejunal mucosa by western blotting after 60 minutes with 6 (30 mmol/L) or without glucose in KH buffer incubation. Solubilized proteins were resolved 7 by electrophoresis on 10% SDS-PAGE gels. Apelin-77 (Abcam 59469) and -actin (Cell 8
Signaling Technology 13E5) antibodies were used at a 1:500 dilution. The intensity of the 9 specific immunoreactive bands was quantified using NIH Image (Scion). of luminal content of PBS-, apelin-or APJ antagonist-gavaged mice were assessed on -23 arrestin 2 recruitment to APJ by BRET. HEK-293T cells were transfected with the human 24 apelin receptor tagged on its C-terminus with the BRET donor Renilla luciferase and β-1 arrestin2 double tagged with the yellow fluorescent protein (YFP) at the N-and C-terminus. 2 BRET approach was assayed as previously described 18 . Intrinsic activities of filtered luminal 3 contents were measured by adding samples 5 min after the Rluc substrate coelenterazine. To 4 determine ifthe antagonist was still active after gavage, luminal content was added 1 min after 5 the luciferase substrate and exogenous [Pyr1]-apelin-13 was added 5 min before reading. 6 7 Apelin assay Apelin was quantified with the non-selective apelin-12 EIA kit (Phoenix 8 Pharmaceuticals, Belmont, CA). Before dosage, luminal content, plasma and conditioned 9 medium were filtrated and concentrated by column (Amicon Ultra, 10,000MWCO, 10 Millipore). 11 12 qPCR experiments Jejunal loops were incubated during 24h in warmed oxygenated KRB 13 containing [Pyr1]-apelin-13 (10 -6 mol/L) or APJ-antagonist (5.10 -6 mol/L) and/or D-glucose 14 (30 mmol/L). After treatment, loops were rinsed in KR buffer and immediately liquid 15 nitrogen-frozen for GLUT2 and SGLT-1 mRNA quantification as previously described. 8 Glucose increases luminal secretion of apelin in vitro and in vivoWhen administrated by 2 gavage to mouse, exogenous glucose promotes apelin luminal secretion. Indeed, 10 minutes 3 after an oral load with high glucose solutions (50 or 100mg in 100 l of water), luminal apelin 4 amount measured in the collected luminal material raised by twofold ( Fig. 1a ). This 5 regulation is glucose-specific and independent of osmolarity since the same concentration of 6 mannitol did not induce apelin secretion (supplemental Fig.S1 ). Consequently, as shown in 7 figure 1b and c, apelin contained in jejunal cell cytoplasm (red)was partially depleted when 8 glucose was orally-given, leading to a significant decrease of immunoreactivity. No staining 9 was observed when the same experiments were performed with preabsorbed immune serum 10 ( Fig. 1b, bottom panel) .Taken together, these results suggest that apelin stored in the 11 epithelial cells (supplemental fig. S2 ) has been released in the lumenin response to glucose. 12
To confirm this hypothesis, we further quantified apelin secretion ex vivo on everted intestine 13 loops from mouse duodenum and jejunum ( Fig. 1e and f ). Both tissues exhibit the same 14 kinetic apelin secretion profile characterized by a dramatic increase of apelin concentration in 15 the medium 30 minutes after incubation of everted loops with 5 or 30 mmol/L glucose 16 solutions. After 60 minutes, similar increase was observed suggesting that maximal release of 17 apelin was reached alreadyafter 30 minutes.Moreover, western blottings showing intracellular 18 form of apelin (dimer of apelin-77; 16kDa) in jejunal-everted loop incubated 60 minutes with 19 30 mmol/L of glucose corroborate these results and reinforce a glucose-dependent apelin 20 release (Fig. 1d) .Then, in order to determine ifimmunoreactive quantification of apelin was 21 specific of one isoform, we performed mass-spectrometry(MS) analysisof gastric secretions 22 collected from PBS-, apelin-or glucose-gavaged mice. AsPyr-1-apelin-13(resulting from a 23 pyroglutamination of apelin-13) is the most stable isoform in aqueous phases, 24 comparisonswere done witha control profile processed with synthetic Pyr-1-apelin-13 alone 25 (data not shown and 20 ) or addedin PBS-treated mice luminal content(figure 2a). Figure  1 2ashows that after purification and filtration steps of gastric secretions, spiked synthetic Pyr-2 1-apelin-13 can be recovered by this technique. Figures 2b and 2e Intestinal glucose physiology is characterized by post-translational regulationofglucose 1 transporter abundance in BBM. We thus examined ex vivo whether apelin modifies glucose 2 transporters amount and activityon jejunal loops. As expected, glucose (10 mmol/l) induced a 3 2.4-fold increase of SGLT-1 amounts in BBM compared to controls (Fig.4a ). Apelin (1 4 nmol/l) alone significantly reduced the basal level of SGLT-1 (p<0.01) and markedly 5 prevented glucose-increase in SGLT-1 abundance (p<0.001) when injected into the loop 3 6 minutes before glucose (Fig. 4a) . 7
The effect of apelin on SGLT-1 activity was then studied using Ussing chamberon mice 8 jejunum isolated. As previously described 11, 12, 21 , the addition of 10 mmol/L D-glucose to the 9 mucosal bath of Ussing chamber induced a rapid and marked increase in Isc (vs. basal 10 conditions), reaching a plateau after 3-4 minutes. Addition of apelin in mucosal compartment 11 3 minutes before glucose challenge markedly reduced the glucose-induced Isc (ΔIsc). As 12 depicted in figure 4b , the inhibition of ΔIsc was dose-dependentwith a maximal inhibition of 13 0.1 µmol/L and an IC 50 of 0.1 nmol/L. Overnight incubation with apelin antibody totally 14 blocked the inhibitory effect of the peptide (Fig. 4c ). Since SGLT-1 expression is balanced 15 byGLUT2 expression 14 , the effect of apelin on GLUT2 was studied. Apelin induces a 16 significant increase in the abundance of GLUT2 in BBM (p<0.05) ( Fig. 4d ). Glucose alone 17 induces a 2.1-fold increase in apical GLUT2 protein andapelin co-incubated with glucose 18 resulted in a significant increase in immunoreactive GLUT2 over the value of glucose or 19 apelin alone indicating an amplification mechanism or additive effects via distinct pathways 20 ( Fig. 4d) . 21
Since AMPK is a key-regulator of glucose transporter in enterocyte, we measured the effect 22 of apelin on the phosphorylation of AMPKα2 subunit. Apelin alone significantly stimulated 23
AMPKα2 phosphorylation (Fig. 4e ). This effect was less marked when compared with 24 glucose alone but when apelin was injected in the jejunal loop together with glucose, the 25 phosphorylation of AMPKα2 was significantly enhanced showing an additive effect of apelin 1 and glucose (Fig. 4e) . 2 3 Apelin stimulates transepithelial transport of 14 C-glucosethrough GLUT2 4 regulationSince AMPKα2 activation is associated with glucose flux control in enterocyte 13 , 5
we investigated[Pyr-1]-apelin-13 effect on transmural hexoses transport (Fig. 5 ). As shown in 6 Fig. 5a , Pyr-1-apelin-13 (1 nmol/L) significantly increased 30 mmol/L glucose uptake in the 7 isolated mice jejunum. This effect was fast (2 min after apelin addition) and glucose specific. 8
Indeed, no effect on 10 mmol/L mannitol uptakewas observed indicating that the increased 9 transport of glucose induced by apelin was unlikely to be caused by changes in paracellular 10 permeability (Fig. 5b) . To better understand the apelin's pathways allowing this glucose flux, 11 we performed the same experiment in presence of phloretin, a GLUT transporter selective 12 inhibitor. The results show that the transepithelial glucose transport stimulated by apelin is 13 significantly decreased to control value in presence of the inhibitor suggesting that GLUT2 14 translocation is necessary for apelin's effect (Fig. 5c) . 15 16 Orally-given apelinincreases intestinal transepithelial glucosetransport from lumen to 17 bloodstreamin mice 18
The net effect of oral apelin on glucose absorption was further investigated. For that purpose, 19 the consequence of an oral administration of Pyr-1-apelin-13 on hepato-portal glucose 20 concentration was studied duringan oral glucose load in fasted mice. Orally-given apelin 21 dramatically increasedglucose concentration in hepato-portal vein15 minutes after glucose 22 load (Fig. 6a) . Then, in order to demonstrate thephysiological effect of endogenous apelin 23 production on intestine glucose uptake,we inhibited theglucose/apelin cycle by using a 24 specific APJ antagonist 19 orally-given 10 minutes before the glucose load.Data presented in 25 figure 6b show that 1 mol/kg antagonist promoted a marked reduction of plasmatic glucose 1 10 and 20 minutes after the glucose load. This result clearly indicates that 2 apelinphysiologically promotes carbohydrates absorption.Finally, to evaluate the long-term 3 effect of both apelin and APJ-antagonist, we studied the consequence of a 24h-treatment on 4 SGLT-1 and GLUT2 mRNA level (Fig. 6c ). As expected, GLUT2 was significantly increased 5 while SGLT-1 mRNA level was decreased by 30 mmol/l glucose. Apelin had the same effect 6 than glucose on carbohydrate transporters mRNA expression.Such effects were blunted by 7 APJ-antagonist treatment. 8 9
Exogenous apelin given by gavage remains active in the proximal intestine 10
To know if exogenous Pyr-1-apelin-13 and APJ-antagonist orally-given to mice are still 11 active when they reach proximal intestine, the luminal content was collected 15 minutes after 12 gavage, purified, filtered and tested for APJ-inducing -arrestin 2 recruitment. Control of cell 13 transfection as well as BRET experiment validity obtained by increasing doses of apelin are 14 presented in supplemental data (supplemental figure S5) . Luminal content collected from 15 Pyr-1-apelin-13 orally-loaded mice displayed a significant rise in BRET signal compared to 16 PBS-stuffed mice, indicating that orally-loaded apelin is active and induces arrestin 17 recruitment to the membrane (Fig. 7a) . Conversely, when APJ-antagonist was given by 18 gavage to mice, the resulting luminal content did not modify basal APJ activity by BRET. 19 Finally, the efficiency of the APJ-antagonist collected after gavage was studied on apelin-20 induced BRET signal (Fig. 7b and c) . As expected, exogenous Pyr-1-apelin-13 added to 21 cells (10 -7 mol/L and 10 -6 mol/L, Fig. 7b and c respectively) induced a significant increase in 22 BRET signal. This effect was totally blunted by lumen content from APJ-antagonist orally-23 loaded mice when 10 -7 mol/L exogenous apelin was used (Fig. 7b.) but not for a higher dose 24 of the peptide (10 -6 mol/L, Fig. 7c ). These results demonstrate that exogenous Pyr-1-apelin-25 13and APJ-antagonist remain efficient when they reach glucose absorption zones of the 1 intestine, i.e. duodenum and jejunum. 2 3 DISCUSSION 1
This study demonstrates the presence of a regulatory intestinal loop between apelin 2 and glucose leading to a rapid regulation of intestinal glucose absorption. In order to 3 insurebalanced glucose absorption during or after a meal, the activity of sugar transporters in 4 the enterocytes appears highly regulated. Indeed, glucose itself is able to promote its own 5 transit through the intestinal barrier towards bloodstream by a fine regulation of SGLT-1 and 6 GLUT2 abundance in the BBM 22 . Recent studies describedotheractors of glucose absorption 7 implicating hormones such as CCK 23 , angiotensin II 24 , insulin 25 , leptin 11 , RELM-β 12 or 8 GLP1/2 26 . Apelinshares characteristics features with these hormones, particularly with leptin, 9 since both are increased with obesity, target the intracellular AMPK and are closely related to 10 glucose homeostasis and insulin sensitivity through their action on skeletal muscle and 11 adipose tissue 9, 27 . In this study, we demonstrate by different approaches that glucose 12 specifically enhances Pyr-1-apelin-13 secretion from intestine cells into the lumenwithout 13 modifications in plasma apelin (supplemental fig. S4 ). This is in line with our previous 14 demonstration that luminal secretion of gut leptin was observed without any modification of 15 blood leptin levels in rat 13 .Eventhough apelin and glucose have been tightly associated in 16 several studies, the direct effect of glucose on a putative apelin secretion has been poorly 17 described. Yamagata et al. have recently shown that human endothelial cultured cells secrete 18 apelin in response to glucose andRingstrom et al. describeda slight increase of mRNA apelin 19 in isolated human pancreatic islets after glucose stimulation 15, 28 . In our study, although 20 concentrations of glucose used ex vivo(30 mmol/L) are physiologically relevant and 21 comparable to other studies 12, 13 , in vivoexperiments required higher doses of glucose (up to 22 100mg/100l) to ensure that a significant amount of glucose reaches small intestine few 23 minutes after oral load. 24 1 luminal leptin secretion in the intestine after fructose load 13 . The question arises of 2 bioavailability of peptides in the lumen characterized by its acidic pH and proteolytic 3 enzymes activity. Interestingly, orally-given apelin remains active as shown by APJ activation 4 and BRET studies. Leptin was shown to besecreted in the lumen together with a soluble 5 receptor allowinga protection from degradation by proteolytic enzymes 29 .It could be 6 hypothesized that such an associated protein could exist for apelin and further consideration 7 to propose pharmacological modulations of luminal free/bound apelin concentrations are 8 needed. 9
This glucose-induced luminal apelin secretion led us to investigate the functional 10 effect of Pyr-1-apelin-13 on glucose absorption. We showed by different approaches that 11 physiological concentration of apelinenhances glucose transmural transport from lumen to the 12 bloodstream.This effect is specific for glucose and not associated with modifications of 13 enterocytes tight-junction's permeability since mannitol is not translocated from the lumen to 14 the serosal side in presence of apelin. Our results also show that, consistently with previous 15 works in muscle and adipose tissue 9, 30 , apelin can also activate AMPK in enterocytes. AMPK 16 is an important glucose sensor in enterocyte 13, 31 and its activation mustinitiate apelin's effects 17 on glucose transportersbalance. Indeed, apelin induces ex vivodecrease of SGLT-1 in BBM 18 whereas GLUT2 expression wasincreased. SGLT-1 is a high-affinity low-capacity glucose 19 carrier constitutively expressed in the BBM of epithelial cell lining the small intestine lumen. 20 SGLT-1 is responsible for luminal glucose uptake against concentration gradient using a 21 membrane potential generated by the sodium pump 32 . Conversely, when glucose 22 concentration increases in the small intestine lumen, mechanisms including PKA, PKCβII and 23
AMPKα2 activation are rapidly activated to traffic GLUT2 into the BBM.The fact that Pyr-24 1-apelin-13 controls SGLT-1's activity and further triggers a switch in glucose transporters 25 SGLT-1/GLUT2 ratio, activities and gene expression, givesa new insight into control of 1 physiological sugar absorption by apelin.It has been reported 16 that GLUT2 is over-expressed 2 in enterocytes during metabolic diseases which could participate to post-absorptive elevated 3 glycemia. Thus, as showed here, pharmacological approach consisting in the blockade of 4 theglucose/apelin cycle by using oral APJ antagonistcould beused to lower glucose 5 absorption. 6
In summary, the present data show the involvement of the apelinergic system in 7 mechanisms controlling the intestinal absorption of glucose. As we recently described a 8 putative role for apelin in glucose uptake in muscle and adipose tissue, it could be 9 hypothesized that apelin firstly acts by enhancing intestinal glucose uptake from digested 10 sugars in order to secondarily furnish energetic substrate to apelin-activated tissues. 
